USNA Usana Health Sciences Inc

  1. Stocks
  2. Consumer Defensive
  3. NYSE: USNA

Price (delayed)

$61.24

Market cap

$1.18B

P/E Ratio

17.01

Dividend/share

N/A

EPS

$3.6

Enterprise value

$893.16M

USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25 ...

Highlights
The quick ratio has grown by 35% YoY and by 2.6% from the previous quarter
The company's equity rose by 10% YoY and by 6% QoQ
The price to earnings (P/E) is 14% higher than the last 4 quarters average of 14.9 but 6% lower than the 5-year quarterly average of 18.1
USNA's net income is down by 40% year-on-year and by 10% since the previous quarter
The EPS has contracted by 38% YoY and by 10% from the previous quarter
Sector: Consumer Defensive
Industry: Household & Personal Products
Website: http://www.usana.com
Peers: NATR NUS PRPH MTEX

Key stats

What are the main financial stats of USNA
Market
Shares outstanding
19.29M
Market cap
$1.18B
Enterprise value
$893.16M
Valuations
Price to earnings (P/E)
17.01
Price to book (P/B)
2.71
Price to sales (P/S)
1.18
EV/EBIT
8.21
EV/EBITDA
6.86
EV/Sales
0.89
Earnings
Revenue
$998.6M
EBIT
$108.81M
EBITDA
$130.22M
Free cash flow
$93.51M
Per share
EPS
$3.6
Free cash flow per share
$4.86
Book value per share
$22.62
Revenue per share
$51.86
TBVPS
$28.4
Balance sheet
Total assets
$596.55M
Total liabilities
$162.08M
Debt
$0
Equity
$434.47M
Working capital
$240.55M
Liquidity
Debt to equity
0
Current ratio
2.67
Quick ratio
2.01
Net debt/EBITDA
-2.21
Margins
EBITDA margin
13%
Gross margin
80.6%
Net margin
6.9%
Operating margin
10.8%
Efficiency
Return on assets
12.1%
Return on equity
16.9%
Return on invested capital
82.1%
Return on capital employed
24%
Return on sales
10.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
-2.52%
1 week
2.03%
1 month
-1.67%
1 year
-24.64%
YTD
15.11%
QTD
15.11%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$998.6M
Gross profit
$804.71M
Operating income
$107.61M
Net income
$69.35M
Gross margin
80.6%
Net margin
6.9%
USNA's net income is down by 40% year-on-year and by 10% since the previous quarter
The operating income has declined by 37% year-on-year and by 8% since the previous quarter
USNA's net margin is down by 30% YoY and by 7% from the previous quarter
Usana Health Sciences's operating margin has decreased by 24% YoY and by 3.6% QoQ

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
P/E
17.01
P/B
2.71
P/S
1.18
EV/EBIT
8.21
EV/EBITDA
6.86
EV/Sales
0.89
The EPS has contracted by 38% YoY and by 10% from the previous quarter
The price to earnings (P/E) is 14% higher than the last 4 quarters average of 14.9 but 6% lower than the 5-year quarterly average of 18.1
USNA's P/B is 42% below its 5-year quarterly average of 4.7 and 13% below its last 4 quarters average of 3.1
The company's equity rose by 10% YoY and by 6% QoQ
USNA's price to sales (P/S) is 26% less than its 5-year quarterly average of 1.6
USNA's revenue is down by 16% year-on-year and by 3.8% since the previous quarter

Efficiency

How efficient is Usana Health Sciences business performance
The ROE has contracted by 41% YoY and by 12% from the previous quarter
Usana Health Sciences's ROA has decreased by 40% YoY and by 11% from the previous quarter
The company's return on invested capital fell by 39% YoY and by 5% QoQ
The ROS has contracted by 24% YoY and by 3.5% from the previous quarter

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The quick ratio has grown by 35% YoY and by 2.6% from the previous quarter
The current ratio has increased by 18% YoY
USNA's debt is 100% less than its equity
The company's equity rose by 10% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.